LSBCF (LakeShore Biopharma Co) Return-on-Tangible-Asset: -17.91% (As of Mar. 2025)


What is LakeShore Biopharma Co Return-on-Tangible-Asset?

LakeShore Biopharma Co LSBCF Return-on-Tangible-Asset is -17.91% as of Mar. 2025. Among 1,418 Biotechnology companies, LakeShore Biopharma Co ranks better than 73.41% on this metric.

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. LakeShore Biopharma Co's annualized Net Income for the quarter that ended in Mar. 2025 was $-33.26 Mil. LakeShore Biopharma Co's average total tangible assets for the quarter that ended in Mar. 2025 was $185.72 Mil. Therefore, LakeShore Biopharma Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was -17.91%.

The historical rank and industry rank for LakeShore Biopharma Co's Return-on-Tangible-Asset or its related term are showing as below:

LSBCF's Return-on-Tangible-Asset is not ranked *
in the Biotechnology industry.
Industry Median: -35.915
* Ranked among companies with meaningful Return-on-Tangible-Asset only.

LakeShore Biopharma Co  (OTCPK:LSBCF) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


LakeShore Biopharma Co Return-on-Tangible-Asset Related Terms


LakeShore Biopharma Co Return-on-Tangible-Asset Historical Data

* Premium members only.

The historical data trend for LakeShore Biopharma Co's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co Return-on-Tangible-Asset Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Return-on-Tangible-Asset
-17.71 -8.77 -9.33 -27.46 -7.28

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only -17.44 -21.31 -35.01 2.96 -17.91

LSBCF vs ACUT, PPCB, ENSC: Return-on-Tangible-Asset Comparison

For the Biotechnology subindustry, LakeShore Biopharma Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LakeShore Biopharma Co Return-on-Tangible-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where LakeShore Biopharma Co's Return-on-Tangible-Asset falls into.



LakeShore Biopharma Co Return-on-Tangible-Asset Calculation

LakeShore Biopharma Co's annualized Return-on-Tangible-Asset for the fiscal year that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Mar. 2025 )  (A: Mar. 2024 )(A: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Mar. 2025 )  (A: Mar. 2024 )(A: Mar. 2025 )
=-13.792/( (200.206+178.611)/ 2 )
=-13.792/189.4085
=-7.28 %

LakeShore Biopharma Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Sep. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Sep. 2024 )(Q: Mar. 2025 )
=-33.262/( (192.831+178.611)/ 2 )
=-33.262/185.721
=-17.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Mar. 2025) net income data.

What does a Return-on-Tangible-Asset of -17.91% mean?
LakeShore Biopharma Co (LSBCF) has a Return-on-Tangible-Asset of -17.91% as of Mar. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on LakeShore Biopharma Co and its competitors. According to the industry distribution chart, LakeShore Biopharma Co ranks #377 out of 1418 companies in the Biotechnology industry, placing it in the top 26.6%.
Is LakeShore Biopharma Co's Return-on-Tangible-Asset too high?
LakeShore Biopharma Co's current Return-on-Tangible-Asset is -17.91%. Based on the distribution chart, LakeShore Biopharma Co ranks #377 out of 1418 companies in the Biotechnology industry, which is above the industry midpoint.
How does LakeShore Biopharma Co's Return-on-Tangible-Asset compare to ACUT and PPCB?
According to the Biotechnology industry distribution chart, LakeShore Biopharma Co ranks #377 out of 1418 companies for Return-on-Tangible-Asset. This puts LakeShore Biopharma Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on LakeShore Biopharma Co and its competitors. LakeShore Biopharma Co's current Return-on-Tangible-Asset is -17.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current Return-on-Tangible-Asset of -17.91%. The current Return-on-Tangible-Asset is -17.91%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current Return-on-Tangible-Asset is -17.91% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LakeShore Biopharma Co Business Description

Address 38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.